



Amendments to the Claims


Claim 1. (currently amended): A compound of formula (I):



wherein:



is an optionally benzo-fused five or six member aromatic ring having zero to three hetero atoms independently selected from N, S, and O



Alk is (C₁₋₄) alkylene or hydroxy substituted (C₁₋₄) alkylene;

X is oxygen or sulfur;

R¹ is hydrogen, (C₁₋₆) fluoroalkyl, (C₃₋₆) cycloalkyl, or (C₁₋₄) alkyl, wherein the (C₁₋₄) alkyl is unsubstituted or substituted with hydroxy, methoxy, ethoxy, OCH₂CH₂OH, or -CN;

R² is H, halogen, (C₁₋₆) fluoroalkyl, (C₃₋₆) cycloalkyl, OR⁴, SR⁴, NO₂, CN, COR⁴, C(O)OR⁴, CONR⁵R⁶, NR⁵R⁶, SO₂NR⁵R⁶, NR⁵COR⁴, NR⁵SO₂R⁴, optionally substituted aromatic, or (C₁₋₆) alkyl, wherein the (C₁₋₆) alkyl is unsubstituted or substituted with hydroxy;

R³ is hydrogen, (C₁₋₄) alkyl, (C₃₋₆) cycloalkyl, (C₂₋₆) alkenyl, Ar, or (C₁₋₄) alkyl-Ar;

R⁴ is hydrogen, (C₁₋₆) alkyl, (C₁₋₆) fluoroalkyl, or optionally substituted aromatic;

R⁵ and R⁶ are independently hydrogen, (C₁₋₆) alkyl, or optionally substituted aromatic,

R^7 is hydrogen, (C_{1-6}) alkyl, (C_{1-6}) fluoroalkyl, or optionally substituted aromatic;

R^8 and R^9 are independently hydrogen, (C_{1-6}) alkyl, or optionally substituted aromatic;

Ar is optionally substituted phenyl, naphthyl, monocyclic heteroaromatic or bicyclic heteroaromatic;

Z^1 and Z^2 are independently selected from hydrogen, halogen, (C_{1-6}) alkyl, (C_{1-6}) fluoroalkyl, OR^7 , SR^7 , NO_2 , CN , COR^7 , $CONR^8R^9$, NR^8R^9 , and optionally substituted aromatic;
~~and all salts, solvates, optical and geometric isomers, and crystalline forms thereof or a~~
pharmaceutically acceptable salt or hydrate thereof.

Claims 2-6. (cancelled)

Claim 7. (previously presented): The compound of claim 1, wherein



Claim 8. (original): The compound of claim 7, wherein:

Alk is (C_{1-4}) alkylene;

X is oxygen;

R^1 is hydrogen or (C_{1-6}) alkyl;


R^2 is hydrogen, (C_{1-6}) alkyl, (C_{1-6}) fluoroalkyl, (C_{3-6}) cycloalkyl, or halogen;

R^3 is hydrogen or (C_{1-4}) alkyl; and

Z^1 and Z^2 are independently selected from hydrogen and halogen.

Claims 9-11. (cancelled)

Claim 12. (previously presented): The compound of claim 1, wherein



Claim 13. (original): The compound of claim 12, wherein:

Alk is (C₁₋₄) alkylene;

R¹ is hydrogen or (C₁₋₄) alkyl;


R² is H, (C₁₋₆) alkyl, halogen, or (C₁₋₆) fluoroalkyl;

R³ is hydrogen, (C₁₋₄) alkyl, (C₂₋₆) alkenyl, or phenyl, wherein (C₁₋₄) alkyl is unsubstituted or substituted with a phenyl group; and

Z¹ and Z² are independently selected from hydrogen and halogen.

Claims 14-20. (cancelled)

Claim 21. (previously presented): The compound of claim 1, wherein



Claim 22. (original) The compound of claim 21, wherein:

Alk is (C₁₋₄) alkylene;

X is oxygen;

R¹ is hydrogen, (C₁₋₆) fluoroalkyl, (C₃₋₆) cycloalkyl, or (C₁₋₄) alkyl, wherein the (C₁₋₄) alkyl is unsubstituted or substituted with a hydroxy, methoxy, ethoxy, or -OCH₂CH₂OH group;

R² is H, (C₁₋₆) fluoroalkyl, (C₃₋₆) cycloalkyl, -C(O)OR⁴, or (C₁₋₆) alkyl, wherein the (C₁₋₆) alkyl is unsubstituted or substituted with a hydroxyl group;

R³ is hydrogen or (C₁₋₄) alkyl;


R⁴ is hydrogen or (C₁₋₆) alkyl; and

Z¹ and Z² are hydrogen.

Claims 23-26. (cancelled)



Claim 27. (previously presented): The compound of claim 1, wherein



Claim 28. (original): The compound of claim 27, wherein:

Alk is (C₁₋₄) alkylene;

X is oxygen;

R¹ is hydrogen or (C₁₋₄) alkyl;

R² is H;

R³ is (C₁₋₄) alkyl; and

Z¹ and Z² are independently selected from the group consisting of hydrogen, halogen and (C₁₋₆) fluoroalkyl.

Claim 29. (cancelled)

Claim 30. (previously presented): The compound of claim 1, wherein the stereo configuration is "S" about the carbon of the piperazine group bound to Alk.

Claim 31. (original): The compound of claim 30, wherein Alk is (C₂₋₄) alkylene.

Claim 32. (previously presented): The compound of claim 1, wherein the stereo configuration is "R" about the carbon of the piperazine group bound to Alk.

Claim 33. (original) The compound of claim 32, wherein Alk is methylene.

Claims 34 – 50. (cancelled)

Claim 51. (previously presented): A pharmaceutical composition comprising an effective amount of a compound according to claim 1 in association with a pharmaceutically acceptable carrier, diluent or excipient.

Claims 52-60. (cancelled)

Claim 61. (Previously presented): A method for treating a psychotic disorder, comprising administering to a mammal in need thereof an effective amount of a compound according to claim 1.

Claim 62. (original): The method of claim 61, wherein the psychotic disorder is schizophrenia.

Claim 63. (original): The method of claim 61, wherein the psychotic disorder is schizophreniform.

Claim 64. (original): The method of claim 61, wherein the psychotic disorder is schizoaffective disorder.

Claims 65-72. (cancelled)

Claim 73. (previously presented): A method for treating a mood disorder, comprising administering to a mammal in need thereof an effective amount of a compound according to claim 1.

Claim 74. (original): The method of claim 73, wherein the mood disorder is a bipolar disorder.

Claim 75. (original): The method of claim 74, wherein the bipolar disorder is acute mania.

Claim 76. (original): The method of claim 74, wherein the bipolar disorder is bipolar depression.

Claims 77-84. (cancelled)

Claim 85. (new): The compound (S)-6-Fluoro-10-[3-(2-hydroxy-ethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene or a pharmaceutically acceptable salt or hydrate thereof.

Claim 86. (new): The compound (S)-10-[3-(2-Methoxymethyl)-4-methylpiperazin-1-yl]-2-isopropyl-4H-3-thia-1,4,9-triazabenzof]azulene or a pharmaceutically acceptable salt or hydrate thereof.